As we know, good-designed randomized clinical trials provide strong evidence that may change the current treatment pattern. Rosell and colleagues conducted direct comparison of paclitaxel/carboplatin versus paclitaxel/cisplatin in advanced NSCLC. 4 The baseline patient's characteristics and follow-up therapy were well balanced between the two treatment arms. The overall response rate in the two arms of paclitaxel/carboplatin and paclitaxel/cisplatin was 28% and 25%, respectively, which was similar. However, patients received paclitaxel/cisplatin had the significantly longer median survival (9.8 months) than paclitaxel/carboplatin (8.2 months). This is confirmed by an individual patient data meta-analysis. 5 In patients with non-squamous histology, cisplatin-based chemotherapy prolonged survival in comparison to carboplatinbased chemotherapy (hazard ratio = 1.12, 95% confidence interval = 1.01-1.23), but not in squamous histology. In our opinion, there are enough evidences to support use of cisplatin in advanced NSCLC, especially in non-squamous histology. In our daily clinical practice, for eligible patients with non-squamous NSCLC, we would like to recommend cisplatin preferentially.
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